Highlights
- Strong demand continues across China and global IMF segments, led by premium products and marketing success
- Supply chain disruptions—including freight, production, and regulatory delays—impact product availability
- FY26 guidance downgraded with lower margins, weaker cash conversion, and delayed sales timing
The a2 Milk Company (NZX:ATM) has reported resilient demand across its infant milk formula (IMF) portfolio, particularly in China, but ongoing supply chain disruptions are weighing on near-term performance. Growth in China-labelled products has been supported by improved user acquisition and strong brand campaigns, while English-labelled products continue to perform well through cross-border e-commerce channels. However, a combination of freight constraints linked to geopolitical tensions, production backlogs from Synlait Milk, stricter quality testing, and extended customs clearance timelines have resulted in product shortages. These challenges are expected to impact availability through the final quarter of FY26. While largely temporary, the disruptions have forced the company to revise its full-year outlook, with weaker revenue growth, lower margins, and delayed cash flows. Despite this, a2 Milk remains committed to investing in long-term brand strength and supply chain improvements.
Why Are Supply Chain Issues Disrupting Growth?
The company’s supply chain has come under pressure due to a convergence of external and internal challenges. Strong demand for IMF products—partly driven by competitor product recalls—has strained inventory levels. At the same time, logistics disruptions, including higher air freight costs and inconsistent sea freight capacity linked to Middle East tensions, have slowed product movement into China. Production has also been impacted by earlier manufacturing constraints at Synlait Milk, leaving a backlog of orders despite recent recovery in output. Additionally, new regulatory requirements, such as enhanced cereulide testing, have extended product release timelines. Increased customs inspections and sampling rates are further delaying distribution. These combined factors are expected to significantly affect China-labelled IMF availability, particularly in April and May, limiting the company’s ability to fully meet demand.
What Does the Revised FY26 Outlook Signal?
The a2 Milk Company has lowered its FY26 expectations as supply disruptions begin to materially affect financial performance. Revenue growth is now forecast in the low to mid double-digit range, while EBITDA margins are expected to decline to around 14.0%–14.5%. Net profit is likely to be flat or slightly lower compared to FY25, reversing earlier expectations of growth. Cash conversion has also been sharply reduced to approximately 50%, reflecting delays in product sales and receipts. While these impacts are largely timing-related, they are difficult to offset in the short term due to long supply chain lead times and proximity to year-end. The company, however, continues to invest in marketing and operational improvements, positioning itself for recovery and growth in FY27 as supply conditions stabilise.
FAQs
Why did The a2 Milk Company lower its FY26 outlook?
The downgrade is mainly due to supply chain disruptions, including freight delays, production backlogs, and stricter regulatory processes in China affecting product availability.
Is demand for a2 Milk products weakening?
No, demand remains strong across China and global markets, especially for premium infant formula products. The issue is supply, not demand.
When are these supply issues expected to resolve?
Most disruptions are temporary and timing-related, with improvements expected as supply chain conditions stabilise and production ramps up in FY27.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
This report (“Report”) has been issued by Kalkine New Zealand Limited (FSP691351) (NZBN:9429047678101) (“Kalkine”). Kalkine is a Financial Advice Provider (“FAP”) and is authorised by a Class 1 Financial Advice Provider Licence issued by Financial Markets Authority (“FMA”) to provide financial advice. Kalkine provides only general financial advice through its research reports following a person becoming a member. The reports contain buy/sell/hold and other recommendations in relation to equity securities, managed funds and other managed investment schemes and other financial advice products. The recommendations and opinions in this Report and on Kalkine website do not take into account any of your investment objectives, financial situation or needs. Before you make a decision about whether to acquire a financial product, you should obtain the Product Disclosure Statement from the product issuer. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. If you act on the advice in the research reports, you may have to pay fees, expenses or other amounts (but not to Kalkine).
The information in this Report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its reports (including this Report), newsletters and websites. All information represents our views at the date of publication and may change without notice.
Kalkine does not issue, sell or deal in any financial products. The information in this Report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain general recommendations to invest in securities and other financial products. Kalkine is not responsible for, and does not guarantee, the performance of, or returns on, any investments mentioned in this Report.
This Report may contain information on past performance of particular investments. Past performance is not a reliable indicator of future performance. Returns stated do not take into account transaction costs and taxes.
Further information about the complaints and dispute resolution process, as well as information about Kalkine’s duties are available on Kalkine’s website. Please read our Financial Advice Provider (FAP) disclosure statement and Complaints Handling Guide, which are available on the website.
Copyright 2026 Krish Capital Pty. Ltd. (ABN 61629651510). All Rights Reserved. No part of this Report, or its content, may be reproduced in any form without our prior consent.